Trials / Completed
CompletedNCT04429984
Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India
A Post Marketing Surveillance (PMS) Study for VPRIV (Velaglucerase Alfa) in India
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 21 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to measure the safety and to find out the effects of VPRIV in participants with Gaucher disease using both retrospective and prospective data when used in the post-marketing setting and to collect genetic mutation data from participants with Gaucher disease. This study is about collecting data available in the participant's medical record as well as data from each participant's ongoing treatment. No study medicines will be provided to participants in this study. When the participants start the study, they will visit the study clinic close to approximately 12 months.
Conditions
Timeline
- Start date
- 2021-07-28
- Primary completion
- 2023-04-22
- Completion
- 2023-04-22
- First posted
- 2020-06-12
- Last updated
- 2023-06-07
Locations
2 sites across 1 country: India
Source: ClinicalTrials.gov record NCT04429984. Inclusion in this directory is not an endorsement.